Popular Trials
Tadalafil for COPD with Pulmonary Hypertension
This trial is testing whether tadalafil can help Veterans with COPD and high blood pressure in the lungs by reducing shortness of breath and improving overall health. The drug works by relaxing blood vessels to improve blood flow. The study will compare tadalafil to another group over several months to see if it makes a significant difference in symptoms and quality of life. Tadalafil received FDA approval in 2009 for the treatment of pulmonary arterial hypertension (PAH) and has shown to improve exercise capacity and quality of life in patients.
Radioisotope Therapy
Rhenium Re 188 P2045 for Lung Cancer
This trial tests a new drug called Rhenium Re 188 P2045 on lung cancer patients. It aims to find a safe dose and check if it helps reduce tumors. Patients are monitored closely for side effects and tumor response.
Behavioral Intervention
Web-Based Educational Program for Respiratory Distress Syndrome
Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is a severe lung condition that causes respiratory failure. Individuals with ALI/ARDS often require the use of a respirator or artificial breathing machine, known as a mechanical ventilator, while in an intensive care unit (ICU). Research has shown that lung protective ventilation (LPV), a type of mechanical ventilation technique, is an effective way to reduce the number of deaths due to ALI/ARDS. This study will evaluate the effectiveness of a Web-based educational program that aims to educate ICU clinicians about the use of LPV in patients with ALI/ARDS.
Popular Filters
Trials for NSCLC Patients
Brachytherapy
CivaSheet for Lung Cancer
This trial will test a new cancer treatment device to see if it is safe and effective. The device uses active components of standard devices in a new way, which may reduce the amount of radiation to healthy tissue while giving a therapeutic dose to diseased tissue.
Kinase Inhibitor
Tepotinib for Lung Cancer
This trial will study the effects of tepotinib on lung cancer growth and spread, as well as safety, side effects, and quality of life. Pharmacogenetic research may also be conducted to study how genes impact the effectiveness of the drug.
Cancer Vaccine
Botanical Supplement for Lung Cancer
This trial is testing whether a dietary supplement consisting of botanicals with known anti-cancer and/or immune-enhancing properties can prolong the survival time of stage IIIB/IV non-small cell lung cancer patients. The supplement will be given to patients in a double-blind fashion, meaning that neither the patients nor the trial staff will know who is receiving the supplement and who is receiving a placebo.
Trials for Non-Small Cell Lung Cancer Patients
Brachytherapy
CivaSheet for Lung Cancer
This trial will test a new cancer treatment device to see if it is safe and effective. The device uses active components of standard devices in a new way, which may reduce the amount of radiation to healthy tissue while giving a therapeutic dose to diseased tissue.
Kinase Inhibitor
Tepotinib for Lung Cancer
This trial will study the effects of tepotinib on lung cancer growth and spread, as well as safety, side effects, and quality of life. Pharmacogenetic research may also be conducted to study how genes impact the effectiveness of the drug.
Cancer Vaccine
Botanical Supplement for Lung Cancer
This trial is testing whether a dietary supplement consisting of botanicals with known anti-cancer and/or immune-enhancing properties can prolong the survival time of stage IIIB/IV non-small cell lung cancer patients. The supplement will be given to patients in a double-blind fashion, meaning that neither the patients nor the trial staff will know who is receiving the supplement and who is receiving a placebo.
Phase 3 Trials
Cancer Vaccine
Botanical Supplement for Lung Cancer
This trial is testing whether a dietary supplement consisting of botanicals with known anti-cancer and/or immune-enhancing properties can prolong the survival time of stage IIIB/IV non-small cell lung cancer patients. The supplement will be given to patients in a double-blind fashion, meaning that neither the patients nor the trial staff will know who is receiving the supplement and who is receiving a placebo.
Immunomodulator
Talactoferrin for Non-Small Cell Lung Cancer
The purpose of the study is to determine whether the combination of talactoferrin, carboplatin and paclitaxel improves progression free survival and overall survival in patients with non-small cell lung cancer compared to the combination of paclitaxel and carboplatin alone
Alkylating agents
Radiation + Chemotherapy for Small Cell Lung Cancer
This trial is testing different radiation therapy regimens to see which is more effective in treating patients with limited-stage small cell lung cancer when given together with chemotherapy.
Trials With No Placebo
Procedure
Cryobiopsy vs Forceps Biopsy for Lung Disease
This trial compares a new method to a standard one for lung biopsies. It targets patients needing lung tissue samples, aiming to improve sample quality and reduce complications. The new method works by freezing and removing tissue, providing larger and higher-quality samples with a good safety and cost-benefit profile.
Brachytherapy
CivaSheet for Lung Cancer
This trial will test a new cancer treatment device to see if it is safe and effective. The device uses active components of standard devices in a new way, which may reduce the amount of radiation to healthy tissue while giving a therapeutic dose to diseased tissue.
Kinase Inhibitor
Tepotinib for Lung Cancer
This trial will study the effects of tepotinib on lung cancer growth and spread, as well as safety, side effects, and quality of life. Pharmacogenetic research may also be conducted to study how genes impact the effectiveness of the drug.
View More Related Trials
Frequently Asked Questions
Introduction to lung
What are the top hospitals conducting lung research?
When it comes to cutting-edge clinical trials in the realm of lung diseases, hospitals across the United States are making significant strides. In New york City, Memorial Sloan Kettering Cancer Center is blazing a trail with its five current active lung trials. While this institution may not have a historical record of past lung trials, their dedication to advancing research in this field is evident. Similarly, M D Anderson Cancer Center in Houston is also at the forefront of innovative lung trials with an equal number of ongoing studies and no previous recorded lung trials.
Meanwhile, on the west coast, PCR Oncology located in Arroyo Grande joins the ranks by conducting five active clinical trials for individuals affected by pulmonary conditions but likewise lacks any prior recorded experiments pertaining to lungs. The University of California Davis Comprehensive Cancer Center in Sacramento reinforces Northern Californian contributions with five currently running lung-related clinical investigations while Washington University School of Medicine based out in St. Louis adds its expertise into mix as well through their own set of five currently underway yet lacking background-controlled comparisons or preceding relevant testing done historically.
These top-tier medical institutions illustrate that groundbreaking advancements do not always require extensive historical data; instead, they highlight an unwavering commitment to progress and improvement within specific areas such as respiratory health. By focusing on these crucial studies today, we pave the way for better treatments and outcomes tomorrow - ensuring brighter horizons for those suffering from lung diseases around the world.
Which are the best cities for lung clinical trials?
When it comes to lung clinical trials, several cities in the United States have emerged as leading centers for research and treatment. Anchorage, Alaska boasts 27 active trials focusing on promising treatments such as Nivolumab, Erlotinib Hydrochloride, and Pembrolizumab. Similarly, Los Angeles, California offers 26 ongoing studies investigating therapeutic options like Erlotinib Hydrochloride and immunotherapies such as Nivolumab and Pembrolizumab. New york City stands out with its 24 active trials exploring innovative treatments including Stereotactic Body Radiation Therapy and targeted therapies like Nintedanib. Finally, Sacramento, California and Chicago, Illinois also contribute significantly to lung clinical trial research with their respective portfolios of 21 and 20 ongoing studies. These cities serve as vital hubs for patients seeking access to groundbreaking lung cancer treatments through participation in clinical trials.
Which are the top treatments for lung being explored in clinical trials?
In ongoing clinical trials, the top treatments being explored for lung cancer display great potential in advancing patient care. One of these leading therapies is durvalumab, an immunotherapy drug that targets specific proteins on cancer cells and has shown promise in multiple studies. Another noteworthy treatment is osimertinib, a targeted therapy designed to inhibit certain genetic mutations commonly found in non-small cell lung cancer (NSCLC). Additionally, lorlatinib, another targeted therapy, has demonstrated encouraging results in trials by targeting specific gene alterations prevalent in metastatic NSCLC patients. These innovative treatments offer hope for improving outcomes and quality of life for individuals diagnosed with lung cancer.
What are the most recent clinical trials for lung?
Exciting advancements are being made in the field of lung cancer research through recent clinical trials. One such trial focuses on the effectiveness of cemiplimab, a potential treatment for lung cancer patients in Phase 2. Another study aims to determine optimal dosages for non-small cell lung cancer (NSCLC) treatment during its Phase 1 dose-finding stage. Additionally, promising results have been observed when combining lorlatinib and ramucirumab as part of a Phase 1 and Phase 2 trial for lung cancer. Further investigation is also underway regarding the potential benefits of tocilizumab in treating this devastating disease, with an ongoing Phase 1 and Phase 2 study. Lastly, furmonertinib at a dosage of 240 mg is undergoing evaluation in a large-scale phase III trial targeting specific subsets within the population affected by lung cancer. These cutting-edge clinical trials offer hope for improved treatments and outcomes for individuals facing this challenging condition.
What lung clinical trials were recently completed?
Recently concluded clinical trials in the field of lung research have yielded significant advancements. These studies demonstrate the commitment of researchers to finding innovative treatments for lung-related conditions. Prominently, a trial led by the Mayo Clinic focused on investigating the effectiveness and safety of a novel therapy targeting specific mutations found in non-small cell lung cancer patients. Furthermore, another trial conducted at Stanford University explored the potential benefits of immunotherapy in individuals with advanced stage small cell lung cancer. These recent breakthroughs provide hope for patients battling these challenging diseases and pave the way for further progress in improving outcomes and quality of life.